Halister News

(Bloomberg) -- Arrowhead Pharmaceuticals rises 8% pre-market on 6.9k volume after William Blair analyst Y. Katherine Xu upgraded the stock to outperform from market perform, PT $6 from $2.

• Says at the R&D day last week, management revealed the TRiM platform for developing novel RNA interference (RNAi) medicines, and promised five INDs or clinical trial application filings in 2018
• Notes the high potency demonstrated from the lead two programs, ARO-AAT and ARO-HBV, in animal models, which are likely to translate into the clinic, given previous experience
• Sees 15% probability of success for ARO-AAT and ARO- HBV and 10% probability of success for the two therapies partnered with Amgen
• Says current cash can sustain operations into mid-2019, when potential initial proof-of-concept data for both ARO-AAT and ARO-HBV read out
• ARWR has 1 buy, 3 holds, no sells, avg PT $2: Bloomberg
• Shares rose 113% YTD while S&P 500 health is up 20%
• NOTE: Sept. 15, Arrowhead Pharma Rises as Cantor is Encouraged By Trial Views
  • Aug. 3, Arrowhead Pharma 3Q Loss Per Share Narrower Than Estimates

To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.net To contact the editors responsible for this story: Arie Shapira at ashapira3@bloomberg.net Steven Fromm